Xintela gets patent grant in Europe for XSTEM stem cell product

Lund, Sweden, 17 March 2021 - Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company's stem cell product XSTEM® consisting of integrin 10-selected mesenchymal stem cells.

Xintela previously announced (October 29, 2020) the preliminary approval of its European patent application from the EPO for the XSTEM stem cell product. Today, the EPO announced that the XSTEM patent has recevied final approval. As a result, Xintela now has patent protection in Europe for XSTEM as a product and for all uses of XSTEM for stem cell therapy. This includes the therapy fields where Xintela is active today: osteoarthritis and other musculoskeletal diseases, diseases of the CNS (Central Nervous System), and the lung complication ARDS (Acute respiratory distress syndrome). The patent is valid until the year 2038.

- This recently approved patent, which protects the stem cell product platform XSTEM for all stem cell therapies, gives us very strong IP protection and is of huge value to Xintela. Together with our own GMP production facility, it secures the development and commercialization of novel therapies from our stem cell platform for many years to come, says Xintela's CEO Evy Lundgren-Åkerlund.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication at 09:15 CET on the 17th of March, 2021.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden

About Xintela
Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM®) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].